Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium

Gonda, Tamas A.; Farrell, James J.; Wallace, Michael B.; Khanna, Lauren G.; Janec, Eileen M.; Kwon, Richard S.; Saunders, Michael D.; Siddiqui, Uzma D.; Brand, Randall E.; Simeone, Diane M.; Ámundadóttir, Laufey T.; Beyer, Georg; Bi, Yan; Brentnall, Teresa A.; Carpizo, Darren R.; Carrato, Alfredo; Chandarana, Hersh; Chun, Jennifer; Chung, Daniel C.; Dudley, Beth; Earl, Julia E.; Everett, Jessica N.; Fava, Melissa; Gaddam, Srinivas; Gallinger, Steve; Golan, Talia; Graff, John J.; Greenhalf, William; Grossberg, Aaron J.; Hart, Philip; Holter, Spring; Huang, Chenchan; Idos, Gregory; Kanth, Priyanka; Kastrinos, Fay; Katona, Bryson W.; Kaul, Vivek; Klute, Kelsey; Kupfer, Sonia S.; Liau, Joy; Lin, James; Lindberg, James; Lowy, Andrew M.; Lucas, Aimee L.; Mayerle, Julia; Merchant, Nipun B.; Paiella, Salvatore; Permuth, Jennifer B.; Schrader, Intan; Sears, Rosalie C.; Siveke, Jens T.; Sussman, Daniel A.; Zogopoulos, George

doi:10.1016/j.gie.2021.10.025

Cited by 15 publications

(7 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 Agreements on diagnostic investigations within the network, together with the dissemination of knowledge and audits concerning protocolbased imaging in the Spoke and the use of standardized reporting templates for CT scans or EUS, could be means to establish an efficient diagnostic workup and better comparability of results across institutions. [16][17][18] This national survey study has several limitations. First, there is a risk of non-response bias.…”

Section: Discussionmentioning

confidence: 99%

Nationwide evaluation of pancreatic cancer networks ten years after the centralization of pancreatic surgery

Hopstaken,

Daamen,

Patijn

et al. 2024

HPB

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Nationwide evaluation of pancreatic cancer networks ten years after the centralization of pancreatic surgery

Hopstaken,

Daamen,

Patijn

et al. 2024

HPB

View full text Add to dashboard Cite

“…The Chi-square test was used to evaluate differences in non-continuous variables (gender) between different groups and t-test for differences in continuous variables (age). Statistical analysis was performed with the RStudio program [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): a decade follow-up of individuals at high-risk for pancreatic cancer

Earl,

Fuentes,

Sanchez

et al. 2024

Familial Cancer

Self Cite

View full text Add to dashboard Cite

The Spanish Familial Pancreatic Cancer Registry (PANGENFAM) was established in 2009 and aims to characterize the genotype and phenotype of familial pancreatic cancer (FPC). Furthermore, an early detection screening program for pancreatic ductal adenocarcinoma (PDAC) is provided to healthy high-risk individuals from FPC and hereditary pancreatic cancer families (first-degree relatives). This article describes our experience over the last 10 years in high-risk screening. Hereditary and familial pancreatic cancer families were identified through the oncology and gastroenterology units. High-risk individuals underwent annual screening with endoscopic ultrasound (EUS) and magnetic resonance (MRI) from age 40 or 10 years younger than the youngest affected family member. Results: PANGENFAM has enrolled 290 individuals from 143 families, including 52 PDAC cases and 238 high-risk individuals. All high-risk individuals eligible for screening were offered to enter the surveillance program, with 143 currently participating. Pancreatic abnormalities were detected in 94 individuals (median age 53 years (29–83), with common findings including cystic lesions and inhomogeneous parenchyma. Imaging test concordance was 66%. Surgical intervention was performed in 4 high-risk individuals following highly suspicious lesions detected by imaging. PANGENFAM is a valuable resource for science innovation, such as biobanking, with clinical and imaging data available for analysis. For high-risk families, it may offer a potential for early diagnosis. Collaboration with other national and international registries is needed to increase our understanding of the disease biology and to standardize criteria for inclusion and follow-up, optimizing cost-effectiveness and efficacy.

show abstract

“…Besides MRI, EUS is used to evaluate the pancreas. In contrast to MRI, establishing clear-cut recommendations for EUS imaging is challenging [ 55 ]. The difficulty stems from the complexity of standardizing EUS procedures as these are strongly dependent on operator expertise, which is a crucial factor in ensuring successful EUS procedures [ 56 ].…”

Section: Surveillance Methodsmentioning

confidence: 99%

“…Clear imaging of the pancreas must first be achieved before any assessment can occur. EUS is used to identify small lesions or as an adjunct for further testing or confirmation when abnormalities are detected on cross-sectional imaging [ 55 ]. While EUS can detect lesions up to < 10 mm, small or deeply located lesions may be difficult to visualize [ 57 ].…”

Section: Surveillance Methodsmentioning

confidence: 99%

Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer

Bogdanski,

van Hooft,

Boekestijn

et al. 2024

Familial Cancer

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths and is associated with a poor prognosis. The majority of these cancers are detected at a late stage, contributing to the bad prognosis. This underscores the need for novel, enhanced early detection strategies to improve the outcomes. While population-based screening is not recommended due to the relatively low incidence of PDAC, surveillance is recommended for individuals at high risk for PDAC due to their increased incidence of the disease. However, the outcomes of pancreatic cancer surveillance in high-risk individuals are not sorted out yet. In this review, we will address the identification of individuals at high risk for PDAC, discuss the objectives and targets of surveillance, outline how surveillance programs are organized, summarize the outcomes of high-risk individuals undergoing pancreatic cancer surveillance, and conclude with a future perspective on pancreatic cancer surveillance and novel developments.

show abstract

Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium

Cited by 15 publications

References 50 publications

Nationwide evaluation of pancreatic cancer networks ten years after the centralization of pancreatic surgery

Nationwide evaluation of pancreatic cancer networks ten years after the centralization of pancreatic surgery

The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): a decade follow-up of individuals at high-risk for pancreatic cancer

Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer

Contact Info

Product

Resources

About